ArticleNature2019
c-Jun overexpression in CAR T cells induces exhaustion resistance.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 584 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
584citing papers in PubMed, 1 pooled it
36.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
584 citing papers in PubMed, 1 synthesis or guideline pooled it, 849 citations in OpenAlex.
- Mapping the clinical landscape of multifunctional CAR T cells: Targets, trends, and synergies.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Pooled it
- The LXRβ/NF-κB axis reprograms CAR-T cells to resist exhaustion in the tumor microenvironment.Oncoimmunology · 2026Article
- CAR-T-centered sequential therapy: current status, challenges, and future clinical perspectives.Journal of hematology & oncology · 2026Review
- Compartment-specific PPARδ activity controls the outcome of cancer-immune cell competition and immunotherapy efficacy.Nature immunology · 2026Article
- SUMO2 deletion changes chromatin accessibility and enhances cytotoxic T cell activation and tumor infiltration.Science advances · 2026Article
- Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.Signal transduction and targeted therapy · 2026Review
- CAR signaling instructs divergent metabolic reprogramming and functional fates in αβ and γδ T cells.Cellular & molecular immunology · 2026Article
- Comparative clinical outcomes and single-cell profiling of CD19 CAR-T versus blinatumomab for relapsed/refractory B-ALL.Journal for immunotherapy of cancer · 2026Article
- Truncating RELA variants drive autoinflammation and autoimmunity by impairing the negative feedback control of NF-κB.JCI insight · 2026Article
- Augmenting CAR T cell functionality and metabolism through CD39 downtuning.Molecular therapy. Oncology · 2026Article
- Generation of Allogeneic CAR-T Circumvents Functional Deficits in Patient-Derived Autologous Product for Glioblastoma.International journal of cancer · 2026Article
- Review
- Barriers and Blueprints: Next-Generation Engineering Strategies for CAR-T Cell Therapy in Gastrointestinal Tumors.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion.Nature communications · 2026Article
- Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases.Stem cell research & therapy · 2026Review
- T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy.Signal transduction and targeted therapy · 2026Review
- Machine learning-driven decoding of maternal immune signatures in repeated pregnancy loss.PLoS computational biology · 2026Article
- Epigenetic insights and innovations for overcoming barriers in CAR-T cell therapy for cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Cell-based cancer immunotherapy: milestones, mechanistic insights, and emerging therapeutic directions.Acta pharmacologica Sinica · 2026Review
- Surfaceome CRISPR activation screening uncovers ligands regulating tumor sensitivity to NK cell killing.Nature communications · 2026Article
524 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
19 authors at 3 institutions in 1 country.
Rachel C LynnStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Evan W Weber *Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Elena Sotillo *Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
David GennertCenter for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.
Peng XuStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Zinaida GoodStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Hima AnbunathanStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
John LattinStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Robert JonesStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Victor TieuStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Surya NagarajaDepartment of Neurology, Stanford University, Stanford, CA, USA.
Jeffrey GranjaCenter for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.
Charles F A de BourcyDepartments of Bioengineering and Applied Physics, Stanford University, Stanford, CA, USA.
Robbie MajznerDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Ansuman T SatpathyCenter for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.
Stephen R QuakeDepartments of Bioengineering and Applied Physics, Stanford University, Stanford, CA, USA.
Michelle MonjeStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Howard Y ChangCenter for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.
Crystal L MackallStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. cmackall@stanford.edu.
Stanford University · USParker Institute for Cancer Immunotherapy · USChan Zuckerberg Initiative (United States) · US
Funding
Special EquipmentP50HG007735 · NHGRI · STANFORD UNIVERSITY · PI CHANG, HOWARD Y · 2014 to 2018
$15.2MCenter for Personal Dynamic RegulomesRM1HG007735 · NHGRI · STANFORD UNIVERSITY · PI CHANG, HOWARD Y · 2019 to 2023
$13.8MHigh Throughput DNA Sequencer UpgradeS10OD018220 · OD · STANFORD UNIVERSITY · PI COLLER, JOHN · 2014 to 2014
$596kHoward Hughes Medical InstituteNHGRI NIH HHS P50 HG007735NHGRI NIH HHS RM1 HG007735NIH HHS S10 OD018220
Abstract
Chimeric antigen receptor (CAR) T cells mediate anti-tumour effects in a small subset of patients with cancer
Indexed as
AnimalsCell Line, TumorEpigenesis, GeneticGene Expression RegulationHumansMiceNeoplasmsProto-Oncogene Proteins c-junReceptors, Antigen, T-CellTranscription Factor AP-1Transcription, GeneticProto-Oncogene Proteins c-junReceptors, Antigen, T-CellTranscription Factor AP-1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.